

# **AN EMPIRICAL PERSPECTIVE ON HEALTH CARE COMPETITION POLICY**

*FTC Health Care and Competition Law and Policy Workshop  
September 9-10, 2002*

Peter J. Hammer, J.D., Ph.D., U. Michigan Law School

William M. Sage, M.D., J.D., Columbia Law School

Supported by an Investigator Award in Health Policy Research  
from the Robert Wood Johnson Foundation

# RELATED PUBLICATIONS

- *Antitrust, Health Care Quality, and the Courts*, **102 COLUM. L. REV. 545 (2002)**
  - empirical assessment of judicial medical antitrust enforcement
- *A Copernican View of Health Care Antitrust*, **65 LAW & CONTEMP. PROB. (2002)**
  - legal and policy issues implicated in constructing an integrated competition policy for health care markets

# What do I mean by empirical?

- What it is: Detailed study of judicial health care antitrust enforcement
  - Objective: assess judicial capacity to address quality and non-price concerns in medical markets
- What it is not: Economic study of health care markets themselves
  - Caveat: we can and do examine the role empirical health services research plays in antitrust litigation

# STUDY OBJECTIVES

- To describe medical antitrust litigation between 1985 and 1999
- To determine how medical antitrust courts address quality and non-price concerns

# STUDY METHODS

- Develop instrument to code judicial opinions
- Identify relevant medical antitrust cases
- Research assistant codes cases *and* identifies text relating to nonprice competition
- Second research assistant double checks coding
- Principal investigators review coding and text excerpts
- Results are compiled and analyzed

# HEALTH CARE ANTITRUST OPINIONS AND DISPUTES

- LEXIS search
  - antitrust and date aft 1/1/85 and date bef 6/1/99 and (physician or hospital or health insur! or HMO or pharmaceutical or nursing or medical device or dentist or chiropractor or mental health)
- 3390 judicial opinions met search terms
- 988 opinions were coded after screen
- 539 opinions were confirmed relevant
- 401 separate disputes represented

# OPINIONS BY COURT

	<u>Opinions</u>	<u>Percent of Total Opinions</u>
<b>U.S. Supreme Court</b>	<b>4</b>	<b>1%</b>
<b>Federal appeals courts</b>	<b>200</b>	<b>37%</b>
<b>Federal district courts</b>	<b>335</b>	<b>62%</b>

# BUSINESS CONDUCT

## Coded Entry by Opinions

	<u>All</u> <u>Opinions</u>	<u>% of</u> <u>Total</u>	<u>Public</u> <u>Opinions</u>	<u>Public</u> <u>Opinions</u>
<i><u>Health professionals</u></i>				
Staff privileges	132	33%	0	0%
Exclusive hospital contracting	132	33%	1	4%
Professional organization rules	11	3%	1	4%
<i><u>Hospitals and health care organizations</u></i>				
Mergers and acquisitions	31	8%	11	42%
Joint ventures	14	3%	1	4%
Joint purchasing	2	0%	0	0%
<i><u>Insurance and managed care</u></i>				
Network participation	20	5%	0	0%
Joint contract negotiation	5	1%	2	8%
Unilateral contract terms	19	5%	2	8%
Payer standards and practices	25	6%	1	4%
<i><u>Information</u></i>				
Private credentialing/accreditation	30	7%	1	4%
Information sharing	7	2%	1	4%
Advertising and marketing	22	5%	1	4%
<i><u>Other</u></i>	95	24%	4	15%

# CONDUCT BY DATE

	<u>1985-89</u>	<u>1990-94</u>	<u>1995-99</u>
<i><u>Health professionals</u></i>			
Staff privileges	49	52	31
Exclusive hospital contracting	41	42	49
Professional organization rules	8	3	0
<i><u>Hospitals and health care organizations</u></i>			
Mergers and acquisitions	5	10	16
Joint ventures	5	6	3
Joint purchasing	0	0	2
<i><u>Insurance and managed care</u></i>			
Network participation	10	4	6
Joint contract negotiation	3	1	1
Unilateral contract terms	5	5	9
Payer standards and practices	15	7	3
<i><u>Information</u></i>			
Private credentialing/accreditation	13	12	5
Information sharing	2	3	2
Advertising and marketing	8	7	7
<i><u>Other</u></i>	27	27	36

# DISPOSITION BY TYPE OF ENFORCEMENT

## Coded Entries by Opinion

	<u>Private litigation</u>	<u>Public litigation</u>
<b>Substantial Outcome For plaintiff:</b> (Denial of defendant's summary judgment motion, Affirmance on Appeal by defendant, Reversal on appeal by plaintiff, Other judgment for plaintiff)	80 (15%)	12 (43%)
<b>Substantial Outcome For defendant:</b> (Grant of defendant's summary judgment motion, Affirmance on appeal by plaintiff, Reversal on appeal by defendant, Other judgment for defendant)	346 (65%)	12 (43%)
<b>Neutral or Non-Dispositive</b>	109 (20%)	4 (14%)

# DISPOSITION BY CONDUCT

## Coded Entries

	<u>Staff Privileges</u>	<u>Exclusive Contracting</u>	<u>Other</u>	<u>Total</u>
<b>Substantial Outcome For plaintiff:</b> (Denial of defendant's summary judgment motion, Affirmance on appeal by defendant, Reversal on appeal by plaintiff, Other judgment for plaintiff)	15 (9%)	30 (16%)	48 (22%)	93 (16%)
<b>Substantial Outcome For defendant:</b> (Grant of defendant's summary judgment motion, Affirmance on appeal by plaintiff, Reversal on appeal by defendant, Other judgment for defendant)	127 (73%)	110 (60%)	127 (59%)	364 (63%)
<b>Neutral or Non-Dispositive</b>	33 (19%)	44 (24%)	40 (19%)	117 (21%)

# **Preliminary Conclusions: Medical Antitrust Litigation**

- **Business conduct:**
  - Litigation is dominated by hospital-related cases involving staff privileges and exclusive contracting.
  - Managed care reflects only a small minority of litigated antitrust cases by comparison.
- **Outcomes:**
  - Plaintiffs lose a disproportionately large percentage of cases, no matter how winning and losing are measured.

# Preliminary Conclusions - cont.

- **Public Antitrust Enforcement:**
  - Only a small percentage of cases are brought by public entities
  - Enforcement agencies are more successful than private plaintiffs in medical antitrust cases, but are less successful than historic benchmarks of federal antitrust enforcement
- **Caveats:**
  - Judicial opinions present only a partial picture of enforcement agency conduct
  - Enforcement agency conduct as a regulator is at least as important as enforcement agency conduct as a prosecutor
  - Further analysis of consent decrees, advisory opinions, guidelines and investigatory decisions will be necessary to gain a complete picture of the significance of public medical antitrust enforcement

# CODING FOR QUALITY

- **Ideological conflicts**

- Professional paradigm: absolutist, objective, quality as “*apart from*” competition
- Antitrust paradigm: quality as “*a part of*” the competitive process

- **Health Services Research**

- Structure (accreditation, ownership, physical facilities)
- Process (tests ordered, malpractice history, preventative services)
- Outcome (mortality, morbidity, surveys and consumer rankings)

- **Economic Perspectives**

- Choice (product differentiation, location)
- Information (credentialling, disclosure)
- Innovation (technological and organizational innovation)

# GENERAL BELIEFS ABOUT COMPETITION

	<u>Coded Entries</u>	<u>% of General Discussions</u>
<u>Orthodox beliefs</u>		
“Competition decreases prices”	58	36%
“Competition decreases costs”	15	9%
“Competition increases quality”	37	23%
<u>Unorthodox beliefs</u>		
“Competition increases prices”	6	4%
“Competition increases costs”	7	4%
“Competition decreases quality”	3	2%
<u>Goldfarbera concerns</u>		
“Apply antitrust laws strictly”	7	4%
“Consider professional issues”	16	10%
“Consider social issues”	11	7%

# Overview Quality Characteristics

- **Firm-Specific Characteristics** (224 entries)
  - Clinical Structure (81 entries)
  - Clinical Process (77 entries)
  - Administration (66 entries)
- **Market-Level Characteristics** (211 entries)
  - Freedom of Choice (72 entries)
  - Range of products and services (21 entries)
  - Informed consumer choice (16 entries)
  - Innovation and R&D (7 entries)

# CLINICAL STRUCTURE (Firm-Specific)

	<u>Coded Entries</u>	<u>% of Quality Discussions</u>
<b>Qualifications of physicians</b>	<b>29</b>	<b>7%</b>
<b>Adequacy of non-physician staffing</b>	<b>11</b>	<b>3%</b>
<b>Continuity of care</b>	<b>11</b>	<b>3%</b>
<b>Adequacy of physical facilities</b>	<b>10</b>	<b>2%</b>
<b>Private accreditation</b>	<b>9</b>	<b>2%</b>
<b>Advanced technology</b>	<b>8</b>	<b>2%</b>
<b>Government certification/licensure</b>	<b>3</b>	<b>1%</b>

# CLINICAL PROCESS (Firm-Specific)

	<u>Coded Entries</u>	<u>% of Quality Discussions</u>
<b>Unspecified process/outcome quality</b>	<b>43</b>	<b>10%</b>
<b>Malpractice history</b>	<b>25</b>	<b>6%</b>
<b>Potential for clinical improvement</b>	<b>6</b>	<b>1%</b>
<b>Ranking in surveys</b>	<b>1</b>	<b>0%</b>
<b>Outcome statistics</b>	<b>1</b>	<b>0%</b>
<b>Preventive services</b>	<b>1</b>	<b>0%</b>
<b>Product defects</b>	<b>0</b>	<b>0%</b>

# ADMINISTRATION (Firm-Specific)

<u>Firm-level administration</u>	<u>Opinions</u>	<u>% of Quality Discussions</u>
General reputation for quality	24	6%
Other	10	2%
Charity care	9	2%
Nonprofit governance	6	1%
Duration of existence (stability)	4	1%
Consumer information	4	1%
Amenities	3	0%
Administrative restrictions	2	0%
Legal rights and remedies	2	0%
Solvency	1	0%
Health education	1	0%
Grievance mechanisms	0	0%

# MARKET LEVEL QUALITY CHARACTERISTICS

	<u>Coded</u> <u>Entries</u>	<u>% of Quality</u> <u>Discussions</u>
Freedom of choice among professionals	72	17%
Unspecified quality of care	27	6%
Range of products and services	21	5%
Overall professional qualifications	18	4%
Informed choice	16	4%
Overall hospital quality	16	4%
Other	14	3%
Location or geographic scope	10	2%
Professionalism	10	2%
Innovation/R&D	7	2%

# Preliminary Conclusions: Antitrust Treatment of Quality

- Orthodox economic beliefs about the effects of competition trump unorthodox beliefs in most medical antitrust cases
- Hospital merger cases reflect substantial, *but isolated*, judicial skepticism about the effects of competition in health care markets
- Judicial Opinions exhibit a tension between treating quality as “apart from” as opposed to “a part of” competition
  - Staff privilege cases -- quality as “*apart from*” competition
  - Exclusive contracting -- quality as “*a part of*” competition

# Preliminary Conclusions: Antitrust Treatment of Quality

- Courts pay almost no attention to quality as it is analyzed in the health services research literature - *clinical structure, process, and outcome measures*.
- Courts employ conventional economic heuristics to assess economic quality concerns - respect for consumer *choice*, belief in the procompetitive effects of *information*, and faith in markets to spawn optimal technological and organizational *innovation*.
- Antitrust law has played only a minor role in addressing quality-related concerns managed care and insurance cases

# Designing A Health Care Competition Policy

- Rethinking Medical Antitrust Law
  - revising antitrust doctrine to better address quality and non-price concerns in health care
  - Integrating antitrust policy with the government’s role as a regulator and purchaser of health care services
- Markets and regulation across a dynamic interface
  - Beyond artificial “boundaries” between market and non-market institutions

# Designing A Health Care Competition Policy - cont.

- Areas of specific concern
  - *Noerr* doctrine invites private manipulation of technological and regulatory parameters
  - Need for a more unified treatment of state regulation and professional self regulation - reforming the state action doctrine
  - Contested role of choice versus standardization in markets for information and insurance
  - Uneasy relationship between antitrust law and agency market failures in health care